New Haven, CT – Rallybio Corporation has announced the acquisition of Candid Therapeutics (https://www.candidrx.com/). According to the company announcement, Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation and hematology. The Companys lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Rallybios pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Rallybio is headquartered in New Haven, Connecticut.

To learn more about Rallybio Corporation, visit https://rallybio.com/
Company LinkedIn Page: https://www.linkedin.com/company/rallybio/

Company Contact:

Rallybio Corporation
234 Church Street
New Haven, CT 6510
203-859-3820

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.